Rare diseases
Investigational molecules
Locations
Recruiting trials first
4 clinical trials in this condition
Czechia
Italy
Belgium
FranceIn short
There are currently 2 ongoing clinical trials for patients with metastatic renal cancer. These studies are testing immunotherapy treatments and targeted therapies for patients with advanced or metastatic clear cell kidney cancer. Trials are taking place across multiple European countries and are evaluating different combinations of medications to help improve treatment outcomes.
This trial is focused on patients with advanced or metastatic clear cell renal cell carcinoma who have already received treatment. Clear cell renal cell carcinoma is a type of kidney cancer that forms in the lining of small tubes within the kidney and has spread to other parts of the body.
Main inclusion criteria:
Main exclusion criteria:
Focus and goal: This study is comparing two different ways of giving nivolumab, an immunotherapy drug that helps the immune system fight cancer. One method involves injecting the medication under the skin (subcutaneous), while the other involves infusing it through a vein (intravenous). The trial aims to determine whether the subcutaneous form is as effective as the traditional intravenous form, potentially offering a more convenient treatment option for patients. Participants will be randomly assigned to receive either form of the medication, and their health and cancer progression will be monitored regularly over several years to gather comprehensive data on the treatment's effectiveness and safety.
Investigational drug: Nivolumab is an immunotherapy medication that helps the body's immune system recognize and attack cancer cells. It works by blocking a protein called PD-1 on immune cells, which enhances the immune system's ability to fight cancer. In this study, nivolumab is being tested in both subcutaneous (under the skin) and intravenous (into a vein) forms to compare their effectiveness in treating advanced or metastatic clear cell renal cell carcinoma.
This trial focuses on patients with advanced or metastatic renal cell carcinoma who have not yet received any treatment for their condition. The study is investigating whether adding a targeted therapy medication to an immunotherapy combination can improve treatment outcomes.
Main inclusion criteria:
Main exclusion criteria:
Focus and goal: This study is comparing two treatment approaches. One group receives a combination of three medications: cabozantinib (taken as a tablet), nivolumab, and ipilimumab (both given as infusions). The other group receives only the two immunotherapy drugs, nivolumab and ipilimumab. The trial is designed as a double-blind study, meaning neither participants nor researchers know which treatment each participant is receiving, to ensure unbiased results. The main goal is to measure how long participants live without the cancer getting worse (progression-free survival) and overall survival. The study will run until December 2025, with regular monitoring visits to assess the treatment's effectiveness and any side effects.
Investigational drugs: Cabozantinib is a targeted therapy medication that works by blocking certain proteins that promote cancer cell growth and blood vessel formation. It is taken orally as a tablet. Nivolumab is an immunotherapy drug given through intravenous infusion that helps the immune system recognize and attack cancer cells by blocking a protein that normally prevents immune cells from doing their job. Ipilimumab is another immunotherapy medication administered intravenously that activates the immune system to fight cancer cells by targeting a different protein that keeps immune responses in check. Together, these medications aim to slow down or stop cancer progression through different mechanisms of action.
Currently, there are 2 active clinical trials available for patients with metastatic renal cancer across Europe. Both studies focus on advanced or metastatic clear cell renal cell carcinoma, which is the most common form of kidney cancer.
A notable feature of these trials is their widespread availability across multiple European countries. The first trial is available in 9 countries (Romania, Czechia, Italy, France, Poland, Finland, Portugal, Spain, and Ireland), while the second trial is available in 9 countries as well (Italy, France, Spain, Finland, Netherlands, Germany, Czechia, Poland, and Belgium). This broad geographic distribution provides patients across Europe with access to these investigational treatments.
The two trials address different patient populations. The first study is designed for patients who have already received treatment and are looking for alternative options, while the second trial is specifically for patients who have not yet received any treatment for their metastatic disease. This means that regardless of where you are in your treatment journey, there may be a trial option available.
Both studies feature nivolumab, an immunotherapy medication, which appears to be a central component in current research for this type of cancer. The first trial is examining different methods of administering nivolumab (under the skin versus through a vein), while the second trial combines nivolumab and ipilimumab with cabozantinib, a targeted therapy. This focus on immunotherapy reflects the current direction of cancer treatment research, which aims to harness the body's own immune system to fight cancer cells.
If you have been diagnosed with metastatic renal cancer, it is worth discussing these trial options with your doctor to determine whether you might be eligible to participate in either study.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
